CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers presented data from clinical trials supporting the chronic use of Soliris® (eculizumab) in a broad range of patients with atypical hemolytic uremic syndrome (aHUS), a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death.
Help employers find you! Check out all the jobs and post your resume.
